Back
HFA Premium Access

Dosing and safety profile of aficamten in symptomatic obstructive hypertrophic cardiomyopathy: results from SEQUOIA-HCM

Session: Late breaking clinical trials: LVAD, HFpEF and hypertrophic cardiomyopathy
Topic: Hypertrophic Cardiomyopathy
Speaker: Doctor C. Coats (Glasgow, GB)
Event: Heart Failure 2024

Congress Presentation

Add to my library

Like

About the speaker

Doctor Caroline Coats

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)
12 presentations
5 followers

9 more presentations in this session

Outcomes with aspirin avoidance after implantation of a Fully Magnetically Levitated LVAD in patients with coronary, cerebral or peripheral vascular disease: the ARIES HM3 randomized clinical trial

Speaker: Professor F. Gustafsson (Copenhagen, DK)

Access
Slides
Video
Like
Thumbnail

Discussant review - ARIES

Speaker: Doctor O. Dar (London, GB)

Access
Slides
Video
Like
Thumbnail

Semaglutide therapy and diuretic use in obesity-related HFpEF: insights from the STEP-HFpEF programme

Speaker: Professor S. Verma (Toronto, CA)

Access
Slides
Video
Like
Thumbnail

Discussant review - STEP-HFpEF Programme

Speaker: Associate Professor D. Farmakis (Athens, GR)

Access
Slides
Video
Like
Thumbnail

Aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM an international multicenter phase 3 trial

Speaker: Doctor M. Maron (Burlington, US)

Access
Slides
Video
Like
Thumbnail

Access the full session

Late breaking clinical trials: LVAD, HFpEF and hypertrophic cardiomyopathy

Speakers: Doctor C. Coats, Professor F. Gustafsson, Doctor O. Dar, Professor S. Verma, Associate Professor D. Farmakis...
Access
Video
Like
Thumbnail

About the event

Image

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources